Loading clinical trials...

Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD) | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD)

A Pilot Study to Evaluate the Safety and Feasibility of Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD)

NCT04047810•Mayo Clinic

View on ClinicalTrials.gov

Summary

Researchers are trying to understand the effects of mesenchymal stem cells therapy in subjects with advance chronic obstructive pulmonary disease

Eligibility

Age

18 - 90 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age range: at least 18 years of age
•Gender: Male or female
•Target disease or condition: Subjects with advance COPD
•Subject must have a post-bronchodilator FEV1/FVC ratio of less than 0.7
•Subject must have a post-bronchodilator FEV1percent predicted value between 20% and 49%.
•Subject must have a total lung capacity (TLC) percent predicted of 80% or more
•Subject must be an ex-smoker, with a cigarette smoking history of ≥ 10 pack-years.
•Subject must have abstained from nicotine products for at least six months prior to enrollment in the study.
•Subjects must score at least 2 in the modified Medical Research Council (mMRC)
•Subjects must have had an exacerbation of COPD within the last 12 months prior to enrollment in the study. An acute exacerbation of COPD is defined as a respiratory event requiring the use of antibiotics or systemic steroids or both.
+5 more criteria

Exclusion Criteria

•Patients with clinically significant illness with manifestations of significant organ dysfunction which in the judgment of the PI or co-investigator would render the study subject unlikely to tolerate the MSC infusion or complete the study
•Subject has been diagnosed with a pulmonary disease other than COPD (e.g. asthma, pulmonary fibrosis, sarcoidosis, pulmonary hypertension, bronchiolitis, interstitial lung disease)
•Subject has been diagnosed with α1-Antitrypsin deficiency
•Subject has a body mass index greater than 35 or less than 16
•Subject has or has had an active infection requiring systemic antibiotics within 12 weeks on enrollment in the study
•Subject has had exacerbation of COPD requiring hospitalization within 12 weeks of enrollment in the study.
•Subject has initiated pulmonary rehabilitation within 12 weeks of enrollment in the study
•Subject uses or used prednisone (or equivalent dose of another corticosteroid) within 12 weeks of enrollment in the study
•Subject has evidence or history of malignancy
•Subject has evidence or history of autoimmune disorders independent of COPD
+9 more criteria

Locations (1)

Mayo Clinic in Florida

Jacksonville, Florida, United States

Key Dates

Start Date

January 6, 2020

Primary Completion Date

November 21, 2023

Completion Date

August 15, 2025

Last Updated

November 14, 2025

Enrollment

ACTUAL participants

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

Mesenchymal Stem Cells

BIOLOGICAL

cfMSC Stem Cell Therapy Targeting COPD

NCT07477600

Chronic Obstructive Pulmonary Disease (COPD)

View study

RECRUITINGPHASE3

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT05878769

Chronic Obstructive Pulmonary Disease

View study

RECRUITINGNA

Probiotics in Pulmonaty Rehabilitation for COPD

NCT06717659

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 14, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD)

Inclusion Criteria

Exclusion Criteria

cfMSC Stem Cell Therapy Targeting COPD

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Probiotics in Pulmonaty Rehabilitation for COPD

A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine

Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH

A Clinical Study of Inhaled Nitric Oxide in Patients With Chronic Obstructive Pulmonary Disease